LATEST DEVELOPMENTS

01/05/14

BigDNA awarded TSB Smart Proof of Market Award

Click here to read more

10/12/12

BigDNA awarded part of €6 million European project to develop new fish vaccines

Click here to read more

01/08/12

BigDNA awarded SMART innovation grant from Scottish Enterprise

Click here to read more

07/12/11

Drs Russell Greig and Alex Chanas join BigDNA Advisory Board

Click here to read more


WELCOME to bigdna ltd

BigDNA Ltd is developing small molecule cancer therapies using a novel delivery and drug activation technology. This proprietary technology aims to increase the therapeutic window of the delivered drug whilst simultaneously reducing non-specific toxicity. BigDNA also retains the rights to its patented phage DNA vaccine technology.

INFORMATION FOR POTENTIAL INVESTORS

BigDNA is a well capitalised company and currently has a diverse, well structured investor portfolio to allow us to develop our platform vaccine technology through phase I trials.

PARTNERING INFORMATION

BigDNA has both a strong, focussed product development program built on key products and an active research arm, whose aim is to develop the core platform technology and to expand the range of vaccines delivered.

SCIENTIFIC INFORMATION

BigDNA actively seeks to work with academic and industrial partners who may be interested in research and development using our novel platform.